Anyang tumor hospital — Anyang, Henan

Public research footprint of Anyang tumor hospital, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Unresectable or Metastatic Gastric or Gastroesophageal Junction… · HR-positive, HER2-negative Metastatic Breast Cancer With Brain… · Locally Advanced or Metastatic Breast Cancer · Solid Tumor Cancer Treatment With Immunotherapy

Recently updated registry entries

NCT07745257 — Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative… (Not Yet Recruiting)
NCT07738679 — Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With… (Not Yet Recruiting)
NCT05920356 — A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Anyang tumor hospital?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 05, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.